Traws Pharma (NASDAQ:TRAW) Announces Quarterly Earnings Results

Traws Pharma (NASDAQ:TRAW) released its earnings results on Monday. The company reported $95.66 EPS for the quarter, beating the consensus estimate of ($7.00) by $102.66, Zacks reports.

Traws Pharma Stock Down 2.3 %

Shares of NASDAQ:TRAW traded down $0.06 during trading on Monday, hitting $2.35. 8,290 shares of the stock were exchanged, compared to its average volume of 155,791. The stock has a market capitalization of $8.56 million, a P/E ratio of -0.02 and a beta of 1.42. Traws Pharma has a 1-year low of $2.02 and a 1-year high of $24.75. The company has a fifty day moving average price of $4.73.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.